Stay Up to Date
with SHINE

When radiation and radiation-emitting substances are used properly by doctors who understand and know how to minimize the health risks, their applications are indispensable in cancer treatment therapies and medical diagnostic imaging.

SHINE to supply n.c.a. Lu-177 for the clinical development of Telix’s investigational radiopharmaceuticals, TLX591 and TLX250

A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale

Janesville Nuclear Tech Company with Fitchburg Ties Pursues ‘Safe, Domestic’ Production of Medical Isotope

Vital medical radioisotope used in over 40,000 medical diagnostic procedures in the United States every day

Molybdenum-99 (Mo-99) is the radioactive isotope that enables many diagnostic nuclear medicine procedures such as SPECT scans, which can detect many potentially life-threatening conditions and help patients receive the potentially life-saving treatments they need.

Our isotope production process is enabling treatment options that have the potential to improve outcomes for patients being treated for a range of cancers.

Uncover the truth about nuclear fusion. Learn why it's safer, cleaner, and closer to reality than you think.

SHINE Medical Technologies LLC today announced that the company has changed its name to SHINE Technologies LLC.

SHINE Medical Technologies continues to make progress toward becoming a fully functioning manufacturer. Friday, it hosted Janesville leaders to a grand opening of its corporate headquarters on its campus on the city’s south side.

The company now has three facilities on its campus on U.S. Highway 51 across from the Southern Wisconsin Regional Airport.

New financing supports SHINE’s commercialization of diagnostic and therapeutic isotope technologies, positions company for growth in development of new fusion-based technologies

SHINE Medical Technologies LLC today announced that it has entered a multi-year contract with the University of Missouri Research Reactor, or MURR®, for irradiation of ytterbium-176.

SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries.

SHINE announced that it has selected the municipality of Veendam in the province of Groningen, the Netherlands, as the location of its European medical isotope production facility.